Introduction
Despite significant progress in the perception, diagnosis and treatment of hypertension, blood pressure monitoring is inadequate in at least half of hypertensive patients [27] . Accordingly, the risks of coronary heart disease, myocardial infarction, cerebral stroke, chronic heart failure (CHF), atrial fibrillation, renal failure and other complications remain uncontrolled. The prevalence of hypertension (HD) in the world is projected to rise to 1.5 billion people by 2025, leading to 7.6 million premature deaths (about 13.5% of the total), 54% of strokes and 47% of events caused by ischemic heart disease [21] .
With an increase in the systolic blood pressure of 20 mmHg, and diastolic -at 10 mmHg the risk of developing cardiovascular disease is doubled [4] . However, today about 9% of patients with arterial hypertension do not know about their high blood pressure [25] .
At rates of growth of morbidity CHF ranks first among all cardiovascular pathology. According to national registries of European countries, the prevalence of this syndrome is 1-9%, its frequency increases with age and after age 65 reaches 10-28%. Probability of death in CHF for a year from the moment of the first clinical symptoms is 10-15% -among all patients, and for 5 years -50%. In severe cardiac decompensation, each second dies for a year. Over the past decade, mortality from this pathology has increased 2-fold. In developed countries, the main causes of CHF are HD and ischemic heart disease [15, 16] . That is why the success in timely diagnosis, prevention and treatment of HD and CHF in its background, is inextricably linked with the results of studying the mechanisms of their occurrence and progression [20] .
The key component of the development of CHF in HD is left ventricular hypertrophy and concomitant recent myocardial fibrosis, which compromises the function of the heart. Fibrosis initially manifests diastolic dysfunction, with progression of the disease, systolic dysfunction occurs [28] .
As a biomarker, a state of connective tissue and, in particular, myocardial fibrosis, has been proposed for galectin-3, which belongs to the family of galectin proteins [5] . It was found that the concentration of galectin-3 in the blood is maximal at the peak of myocardial fibrosis and inflammation that arises as a result of heart failure [2, 14] . It is believed that galectin-3 reflects central processes mediating nonadaptive cardiac remodeling [7] . Several studies have shown that galectin-3 markers of increased mortality and left ventricular remodeling in patients with and without CHF of different etiology [3, 26, 30] . According to Kubanek M. et al. [17] galectin-3 plays an important role in the initial stages of heart failure formation and is an important predictor of left ventricular hypertrophy. One of the certain limitations in estimating the prognostic value of galectin-3 is the dependence on sexual and age-related differences, as well as on the size of renal glomerular filtration [19] .
Objective: to improve prediction of the course and effectiveness of therapy for hypertension and chronic heart failure, which is its complication in men 40-60 years by applying the level of galectin-3 as a biomarker.
Materials and methods
The study was performed according to the standards of proper clinical practice and the principles of the Helsinki Declaration. A written informed consent was received before enrollment of participants in the study.
The following males -residents of Podillya region were studied: 79 men aged 40-60, average age 57.06 ± 0.50 years, with no signs of cardiovascular disease, 62 men, average age 49.19 ± 0.66 years, with stage II hypertensive disease and 50 men, average age 50.14 ± 0.99 years, with HD complicated by CHF. During enrollment of males in the groups of patients with stage II HD and HD complicated by CHF, the following factors were considered: verified diagnosis of HD (with obligatory exclusion of symptomatic hypertension), the presence of LVH, confirmed by clinical and instrumental examinations. Exclusion criteria were symptomatic arterial hypertension, impaired renal function and liver, coronary heart disease developed prior to HD, endocrine, hematological, neoplastic and autoimmune disorders, complications of HD -myocardial infarction, acute cerebrovascular accident. In study patients with HD, the diagnosis of concomitant coronary artery disease was excluded after assessment of pre-test probability of the disease on the basis of simple clinical indicatorscomplaints, anamnesis of the disease, detailed data analysis of outpatient cards of patients, results of ECG at rest and ultrasound examination of the heart at rest [10] .
All the males were inpatients at Vinnytsia Regional Specialized Clinical Hospital of Radiation Protection of Ministry of Health of Ukraine and Military Medical Clinical Center of Central Region of Air Forces of Ukraine, and were also observed on outpatient basis from December 2013 to July 2014.
Plasma galectin-3 concentration of study patients was determined by enzyme-linked immunoassay using standard set of reagents produced by Bender MedSystems GmbH (Austria), and "Stat Fact 330" apparatus. Detection of galectin-3 level is indicated in attestation certificate of the laboratory. Reference value of plasma galectin-3 concentration -0.0 -2.28 ng/ml, average level -0.54 ng/ml.
Blood sampling was done in fasting state from cubital vein in the amount of 2ml whole blood at 8 a.m. Then 0.5 ml of plasma was separated, time between sampling of whole blood and plasma separation was less than 30 min. The separated plasma was frozen at -25°С.
Electrocardiogram registration was done according to conventional method using 12 standard leads. Blood pressure was measured according to recommendations of WHO experts. Evaluation of parameters of systemic and intracardiac hemodynamics was performed using echocardiography on echogram "RADMIR ULTIMARA" (Kharkiv, Ukraine). Left ventricular muscle mass index (LVMMI) was calculated using Penn Convention formula. LVMMI > 115g/m 2 was considered the criterion of LVH for males according to clinical recommendations of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) to treatment of arterial hypertension (2013, 2016) [9, 22] .
Moderate hypertrophy of the left ventricle was established at the value of the index of left ventricular myocardial mass to 170 g/m [23] . In the pulsed Doppler regime, the transdermal flow parameters were studied: the maximum speed of rapid early diastolic filling (E) and the maximum rate (A) of left ventricular filling during left systole (cm/s), their ratio (E/A). Diastolic function of the left ventricle was evaluated in accordance with the current recommendations [12] . The state of the systolic function of the left ventricle myocardium was estimated by the indicator of the ejection fraction. The systolic function was considered to be preserved when the fraction rate exceeded 40%. In determining the boundary level of the galectin-3 in blood plasma, the formula proposed by Antonomov M.Yu. and others. [1, 29] : X = [(M1 + 2 m1) + (M2 -2 m2)] / 2, where X is the boundary level of the galectin-3; M1 -the average value of level of the galectin-3 in the group with the absence of the sign (conditionally healthy); m1 -the standard deviation M1; M2 -the average value of the level of galectin-3 in the group with the presence of a sign (conditionally ill); m2 -M2 the standard deviation.
All patients were prescribed baseline therapy in accordance with the recommendations of the Ukrainian Association of Cardiologists (2014) To evaluate the treatment efficacy, clinical criteria were developed for which the changes in the concentration of the biomarker of galectin-3 were considered. In the first stage, 2 graduations of patients were selected: the first -persons with a good effect of treatment in which the target blood pressure level < 140/90 mm Hg was reached and a decrease of 1 functional class for NYHA in the presence of CHF. The second (moderate effect) patients whose arterial pressure decreased by 10% and more but the target pressure was not achieved and the decrease in CHF patients in the functional class I and more.
Statistical analysis included calculation of primary statistics, detection of differences between groups by statistical characteristics, determining the relationship between variables using parametric (Pearson correlation) and nonparametric (Spearman correlation) analysis. For quantitative indicators, the primary statistical processing included the calculation of the arithmetic mean (M), the standard deviation (m), the mean-square deviation (σ). The differences between the samples, distributed according to the law of normal distribution, were evaluated for Student's t-criterion (t) for unrelated measurements. Using a regression analysis, a mathematical model of the effect on the galectin-3 studied factors in patients with HD was determined. R2 is a determination coefficient whose value is from 0 to 1 and the closer the value to 1 is the stronger the connection. F -Fischer's criterion is a parametric criterion and is used to compare the variances of the two variation series. The regression equation has the following form: Y = a + b´ X, where y -is a dependent variable, x -is an independent variable, a -is a free member, and b -is a regression coefficient.
Mathematical processing was performed on a personal computer using standard statistical package "Statistica 10.0".
For initial preparation of tables and intermediate calculations Microsoft Excel package was used.
Results
The use of biological markers that reflect different aspects of the pathogenesis of CHF should be considered as a priority area in identifying patients at high risk of adverse clinical states, as well as for biomarker-controlled therapy and monitoring the feasibility of the therapy.
It was interesting to determine what affects the level of galectin-3. Using a method of stepwise multiple regression with the inclusion of predictors, the analysis developed a mathematical model for the effect on the concentration of galectin-3 in plasma blood factors in patients with HD II. In the uncomplicated course of the disease, the equation has the form: .14%, p < 0.05, F=14.47), where, y 2 -level of galectin-3 (index of dependent variable); x 1 -emission fraction in %; x 2 -is a very low density lipoprotein cholesterol, mmol/l; x 3 -shock volume, ml; x 4 -heart rate, bpm; x 6 -systolic blood pressure, mmHg.; x 7 -age, years; x 8 -is a functional class; x 9 -index of left ventricular myocardial mass g/m 2 ; x 10 -thickness of interventricular septum, mm; x 11 -total cholesterol, mmol/l. Table 1 shows levels of galectin-3 before and after 6 months of treatment.
According to the findings, a higher level of galectin-3 was observed in patients with HD complicated by CHF compared to patients with uncomplicated HD. At the same time, the concentration of galectin-3 significantly decreases against the background of treatment. The level of blood in the galectin-3 in patients with HD II stage was close to normal values, and in patients with HD III stage slightly exceeded it.
Depending on the effectiveness of the therapy, levels of galectin-3 are shown in Figure 1 .
The above data became the basis for calculating the boundary level of galectin-3, which could contribute to the prediction of treatment efficacy: the level of galectin-3 ? 46.51 pg / ml (sensitivity 94.0%, specificity -84.2%, errorfiction -60.7%, false-negative response -6.0%, falsepositive response -15.8%) suggests a moderate effect on treatment in male patients of patients with HD and CHF.
Determination of the boundary level of galectin-3 in a patient before treatment will allow to select those who start therapy can not immediately give a good effect and it is better for them to apply more aggressive therapy.
Discussion
According to the data received by De Boer R. A. et al. [6] galectin-3 showed the highest degree of correlation with the severity of diastolic dysfunction (high E/Ea) compared to other echocardiographic parameters. In the course of clinical trials, it has been found that expression of galectin-3 increases in patients with a lower left ventricular ejection fraction, regardless of the etiology of heart failure. Also in research by De Boer R. A. and et al. [8] it was found that the concentration of galectin-3 is a phenotypic trait that reflects the intensity of cardial and vascular remodeling processes and may help to detect disturbances in the contractile and relaxation capacity of the myocardium, such as the left ventricular ejection fraction or peak systolic, early and late diastolic velocity.
In our opinion, the etiological factor imposes an imprint on the expressiveness of the fibrotic processes in the myocardium. In particular, as shown in Table 1 in patients with HD of stage II, that is, in the presence of left ventricular hypertrophy. Even without signs of CHF above and functional class, the level of galectin-3 was higher than that of people without cardiovascular disease of the same age. Thus, galectin-3 can mark and present a left ventricular hypertrophy caused by HD.
At the same time, in relation to the dynamics of the level of galectin-3 in plasma, which were obtained in a small number of studies on the background of ongoing therapy, are contradictory. Thus, the ability of galectin-3 to predict the efficacy of CHF pharmacotherapy was studied in a study of Cardiac Resynchronization in Heart Failure (CARE-HF) to study the level of galectin-3 in plasma when performing resynchronization therapy, and included 250 people who had resynchronized therapy, however, no significant changes in the level of galectin-3 were found [11] .
In the Deventer-Alkmaar heart failure study (DEAL-HF), 232 patients with NYHA functional class III-IV CHF were included, correlation between the dynamics of the level of galectin-3 in plasma during 12 months of follow-up (3 and 12 months), dynamics left diastolic volume of the left ventricle and left ventricular remodeling parameters were not noted. However, this again did not take into account again the etiology of CHF [18] . The controversial data from the Framingham study were surveyed of 3353 individuals (59 years of age, 53% women), an association between the level of galectin-3 and left ventricular mass was found [13] .
V. Y. Tsuleiko et al. [24] showed that the level of galectin-3 in patients with CHF in 6 months. against the background of treatment showed a decrease of 1.5 times in patients with adequately selected therapy and amounted to 29.94 ng/ml, while patients who did not receive targeted doses of drugs, on the contrary, increased to 34.74 ng/ml.
Thus, the level of galectin-3 in blood plasma, according to several researchers, marks not only CHF as such, but also can reflect the effectiveness of treatment. According to the results of the study, the level of plasma in the blood of galectin-3 can be applied to predict the treatment of patients with HD and CHF. Table 1 . Levels of galectin-3 before and after 6 months of treatment in patients with HD (M±σ).
Notes: (1) , (2), (3), (4), (5) Fig. 1 . Levels of galectin-3 in blood plasma after treatment in men with HD II and III stages, depending on the effectiveness of treatment, ng/ml.
Notes: # -the difference between the indices is reliable when comparing the levels of galectin-3 in individuals with HD of stage II, * -the difference between the indices is reliable when compared within a group. 2. The biomarker galectin-3 can be used to effectively predict the efficacy of treatment both in asymptomatic HD and in the development of CHF in its background.
